Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4081/mrm.2020.693 http://scihub22266oqcxt.onion/10.4081/mrm.2020.693 32983456!7512942!32983456     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Multidiscip+Respir+Med 2020 ; 15 (1): 693 Nephropedia Template TP {{tp|p=32983456|t=2020. High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 |pdf=|usr=}}{{32983456}} gab.com Text High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 JO: Multidiscip Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=32983456 #FOAvip INTRODUCTION: High-flow nasal cannula oxygen therapy (HFNC) has been shown to be a useful therapy in the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), but its efficacy is still unknown in patients with COVID-19. Our objective is to describe its utility as therapy for the treatment of ARDS caused by SARS-CoV-2. METHODS: A retrospective, observational study was performed at a single centre, evaluating patients with ARDS secondary to COVID-19 treated with HFNC. The main outcome was the intubation rate at day 30, which defined failure of therapy. We also analysed the role of the ROX index to predict the need for intubation. RESULTS: In the study period, 196 patients with bilateral pneumonia were admitted to our pulmonology unit, 40 of whom were treated with HFNC due to the presence of ARDS. The intubation rate at day 30 was 52.5%, and overall mortality was 22.5%. After initiating HFNC, the SpO(2)/FiO(2) ratio was significantly better in the group that did not require intubation (113.4+/-6.6 vs 93.7+/-6.7, p=0.020), as was the ROX index (5.0+/-1.6 vs 4.0+/-1.0, p=0.018). A ROX index less than 4.94 measured 2 to 6 h after the start of therapy was associated with increased risk of intubation (HR 4.03 [95% CI 1.18 - 13.7]; p=0.026). CONCLUSION: High-flow therapy is a useful treatment in ARDS in order to avoid intubation or as a bridge therapy, and no increased mortality was observed secondary to the delay in intubation. After initiating HFNC, a ROX index below 4.94 predicts the need for intubation. Twit Text FOAVip High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 ????Multidiscip Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=32983456 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32983456 #FOAvip English Wikipedia <ref>{{Cite pmid|32983456}}</ref> High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 #MMPMID32983456 Panadero C; Abad-Fernandez A; Rio-Ramirez MT; Acosta Gutierrez CM; Calderon-Alcala M; Lopez-Riolobos C; Matesanz-Lopez C; Garcia-Prieto F; Diaz-Garcia JM; Raboso-Moreno B; Vasquez-Gambasica Z; Andres-Ruzafa P; Garcia-Satue JL; Calero-Pardo S; Sagastizabal B; Bautista D; Campos A; Gonzalez M; Grande L; Jimenez Fernandez M; Santiago-Ruiz JL; Caravaca Perez P; Alcaraz AJ Multidiscip Respir Med 2020[Jan]; 15 (1): 693 PMID32983456show ga INTRODUCTION: High-flow nasal cannula oxygen therapy (HFNC) has been shown to be a useful therapy in the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), but its efficacy is still unknown in patients with COVID-19. Our objective is to describe its utility as therapy for the treatment of ARDS caused by SARS-CoV-2. METHODS: A retrospective, observational study was performed at a single centre, evaluating patients with ARDS secondary to COVID-19 treated with HFNC. The main outcome was the intubation rate at day 30, which defined failure of therapy. We also analysed the role of the ROX index to predict the need for intubation. RESULTS: In the study period, 196 patients with bilateral pneumonia were admitted to our pulmonology unit, 40 of whom were treated with HFNC due to the presence of ARDS. The intubation rate at day 30 was 52.5%, and overall mortality was 22.5%. After initiating HFNC, the SpO(2)/FiO(2) ratio was significantly better in the group that did not require intubation (113.4+/-6.6 vs 93.7+/-6.7, p=0.020), as was the ROX index (5.0+/-1.6 vs 4.0+/-1.0, p=0.018). A ROX index less than 4.94 measured 2 to 6 h after the start of therapy was associated with increased risk of intubation (HR 4.03 [95% CI 1.18 - 13.7]; p=0.026). CONCLUSION: High-flow therapy is a useful treatment in ARDS in order to avoid intubation or as a bridge therapy, and no increased mortality was observed secondary to the delay in intubation. After initiating HFNC, a ROX index below 4.94 predicts the need for intubation. äHigh-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS)(epmc).pdf DeepDyve Pubget Overpricing